Top Health Fitness Tips

A Practical Guide to Managing Side Effects in the First 90 Days of GLP-1 Therapy

Image default
Health

By Dr. Quoc Dang, DO — Medical Director, WeightLossPills.com

The first three months of GLP-1 therapy are, for most patients, the hardest part. Not because the medication is not working but because the body is adjusting to something genuinely new, and that adjustment process comes with a set of side effects that can range from mildly inconvenient to temporarily disruptive.

The good news is that these side effects are almost always temporary, manageable with the right approach, and by no means a reason to give up on treatment. The bad news is that without guidance, a lot of patients do give up in those first weeks, concluding that the medication is not for them when they were actually weeks away from turning the corner.

Here is a practical guide to what to expect and how to navigate it.

Nausea: The Most Common Complaint

Nausea is the side effect most commonly reported in clinical trials and in my practice. It typically begins in the first week or two of treatment and often peaks during dose escalation periods before fading as the body adapts. For some patients it is mild, a background queasiness that does not significantly interfere with daily life. For others it is more pronounced, particularly in the morning or after eating.

The most effective strategies for managing nausea: eat smaller portions than you are accustomed to, particularly in the early weeks. The medication slows gastric emptying, meaning food stays in the stomach longer. Eating the same volume you were eating before the medication started is a reliable way to feel terrible.

Avoid high fat and heavily fried foods, which are processed more slowly and seem to trigger nausea more reliably than lighter options. Eat slowly and chew thoroughly. Avoid lying down within an hour or two of eating. Ginger tea, ginger chews, and over the counter products like Dramamine can help manage nausea acutely.

Staying well hydrated is also important, both because dehydration worsens nausea and because GLP-1 medications can reduce fluid intake along with food intake in ways patients do not always notice.

Constipation: The Often Overlooked Problem

Because GLP-1 medications slow gastric motility throughout the digestive tract, constipation is extremely common and often underreported by patients who either do not connect it to the medication or feel too embarrassed to mention it. I always ask about it directly.

The solutions are straightforward but require consistency. Fiber intake needs to be adequate, ideally through whole foods including vegetables, fruits, and legumes, with psyllium supplement as a backup if needed. Hydration is essential. Walking and physical activity help move things along. If dietary measures are not enough, a gentle osmotic laxative like polyethylene glycol is generally safe and effective.

Constipation that goes unmanaged can become genuinely uncomfortable and is a common reason patients feel unwell on GLP-1 therapy. Managing it proactively from the start of treatment is much easier than trying to catch up after the fact.

Fatigue in the Early Weeks

Some patients experience meaningful fatigue in the first weeks of treatment, particularly if they have reduced their food intake substantially. The body is getting fewer calories, sometimes significantly fewer, and that has energy implications. Fatigue can also be related to electrolyte shifts or to the early phase of fat mobilization.

My advice: do not interpret early fatigue as a sign the medication is harming you. Do make sure you are eating enough, because some patients restrict food so aggressively in the first weeks that they are genuinely undernourished. Eating adequate protein and not skipping meals entirely, even when appetite is very low, helps stabilize energy levels.

Dose Escalation and Why It Matters

GLP-1 medications are started at low doses and increased gradually over a period of months. This titration process exists precisely to minimize side effects. Pushing the dose escalation faster than recommended is one of the most reliable ways to make side effects worse.

If your side effects are significant at your current dose, the right response is usually to stay at that dose for longer, not to push through to the next increment. I have had patients tell me their previous provider increased the dose on schedule regardless of how they felt, resulting in weeks of misery that could have been avoided. The titration schedule is a guideline, not a mandate.

When to Call Your Doctor?

Most GLP-1 side effects are uncomfortable but not dangerous. There are exceptions. Severe abdominal pain, particularly pain that radiates to the back or is accompanied by vomiting, should be evaluated promptly as it can indicate acute pancreatitis. Signs of severe dehydration, extreme weakness, or persistent vomiting that prevents keeping any food or water down also warrant contact with your provider.

For patients who want to understand side effect profiles across different types of weight loss medication before starting treatment, having that information in advance means fewer surprises and better preparation for what the first 90 days may feel like.

The Turn-Around Point

Most patients who stay with GLP-1 therapy through the first two to three months describe a meaningful improvement in how they feel once the body has adapted and the dose is stable. The nausea fades. The constipation improves with better management. Energy returns. The appetite changes that were disorienting at first become familiar and even welcome.

I tell every new patient the same thing: the first months are an adjustment, not a permanent state. If you can get through the adaptation period with appropriate strategies in place, the experience of being on this medication looks very different from those early weeks. Most patients who stick with it are glad they did.

Dr. Quoc Dang, DO, is a board-certified physician and Medical Director at WeightLossPills.com, where he specializes in medically supervised weight management and GLP-1 therapy.